Key points are not available for this paper at this time.
In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of
Share your take
Add a clinician perspective alongside expert commentary.
Wiesenfarth et al. (Thu,) studied this question.